Riskpilot← Back to searchSign inGet full accessLAUSTSEN VENTURES ApS
APSActiveCVR 35408975Lundtoftevej 153BEngineering activities and related technical consultancy · NACE 7112Est. 2013— employees
Revenue 2024
DKK -13K
-26% vs 2023
EBITDA margin
100.0%
+26% vs 2023
Equity ratio
-27.4%
Financial strength
Net profit 2024
DKK -96K
-5% vs 2023
| Revenue | DKK -13K | -26% |
| EBITDA | DKK -13K | +26% |
| Net profit | DKK -96K | -5% |
| Total assets | DKK 1,5M | +3% |
| Equity | DKK -400K | -32% |
| Employees | — | — |
Legal name
LAUSTSEN VENTURES ApS
CVR number
35408975
Legal form
Anpartsselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
5. august 2013
Share capital
DKK 80.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren, Andreas Hougaard Laustsen.
Company purpose
Selskabets formål er at drive konsulentvirksomhed inden for bioteknologi og lægemiddeludvikling og medicoteknologi samt eje ejerandele af andre selskaber.
Address
Lundtoftevej 153B
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 133 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -23 | -18 | -17 | -12 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 133 | 0 | 0 | 0 | -0 | -0 | -5 | 0 | -23 | -18 | -17 | -12 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 133 | 0 | 0 | 0 | -0 | -0 | -5 | 0 | -23 | -18 | -17 | -12 |
| Net financials | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -79 | -54 | -70 | -75 | -83 |
| Profit before tax | 133 | 0 | 0 | 0 | -0 | -0 | -5 | -79 | -77 | -89 | -91 | -96 |
| Tax | 33 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | 100 | 0 | 0 | 0 | -0 | -0 | -5 | -79 | -77 | -89 | -91 | -96 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 100 | 100 | 100 | 100 | 290 | 298 | 649 | 848 | 861 | 967 | 1.415 | 1.460 |
| Equity | 100 | 100 | 100 | 100 | 100 | 100 | 92 | -47 | -124 | -213 | -304 | -400 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 0 | 190 | 198 | 557 | 895 | 986 | 1.180 | 1.720 | 1.861 |
| Total debt | 0 | 0 | 0 | 0 | 190 | 198 | 557 | 895 | 986 | 1.180 | 1.720 | 1.861 |
EBITDA margin
-1250000.0%
This company
15.8%
Market median
-7911492% vs market
20132024
Equity ratio
-27.4%
This company
38.2%
Market median
-172% vs market
20132024
Return on equity
-9597100.0%
This company
18.4%
Market median
-52158252% vs market
20132024
Net profit margin
-9597100.0%
This company
8.1%
Market median
-118482816% vs market
20132024
Asset turnover
-0.01×
This company
1.12×
Market median
-101% vs market
20132024
Debt / equity
4.65×
This company
0.62×
Market median
-650% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-08-05 – 2013-12-31
No data on file.
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
LAUSTSEN VENTURES ApS 
VenomAid Diagnostics ApSBoard members of LAUSTSEN VENTURES ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|